Improving survival with metformin: The evidence base today

Diabetes and Metabolism

Volumn 29, Issue 4 II, 2003, Pages

  Scarpello, J H B ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Diabetic complications; Macrovascular; Metformin; Microvascular; Type 2 diabetes

Indexed keywords

INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

DIET THERAPY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SURVIVAL RATE; TREATMENT CONTRAINDICATION; UNITED KINGDOM;

EID: 18144449490     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(03)72786-4     Document Type: Review

References (25)

1. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. Br Med J, 1993, 306, 1313-18.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993, 16, 434-44.
3. Adler AI, Neil AW, Manley SE, Holman RR, Turner RC. Hyperglycaemia and hyperinsulinaemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J, 1999, 138, S353-9.
4. Haffner SM, Lehto S, Rönemma T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998, 339, 229-34.
5. Donnan PT, Boyle DI, Broomhall J, et al. Prognosis following first acute myocardial infarction in type 2 diabetes: a comparative population study. Diabet Med, 2002, 19, 448-55.
6. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1987, 30, 123-31.
7. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-53.
8. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-65.
9. Stratton IM, Holman RR. The cardioprotective effects of metformin may not be dose-dependent [Abstract]. Diabet Med, 2003, 20 (suppl. 2), A55.
10. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Brit J of Diabetes Vasc Dis, 2001, 1, 28-36.
11. UKPDS Correspondence. Lancet, 1998, 352, 1932-4.
12. Sgambato S, Varricchio M, Tesauro P, Passariello N, Carbone L. Use of metformin in ischemic cardiopathy. Clin Ther, 1980, 94, 77-85.
13. Montaguti U, Celin D, Ceredi C, Descovitch GC. Efficacy of the longterm administration of metformin in hyperlipidaemic patients. Res Clin Forums, 1979, 1, 95-103.
14. Blackburn H, Keys A, Simonson E, Rautaharju E, Punsar S. The electrocardiogram in population studies. A classification system. Circulation, 1960, 21, 1160-75.
15. Charlon V, Boucher F, Mouheddine S, De Leiris J. Reduction of myocardial infarct size in rats submitted to permanent left coronary artery ligation. Diabete Metab, 1988, 14, 591-5.
16. Malmberg K for the DIGAMI study group. Prospective randomised study of intensive insulin treatment on longterm survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J, 1997, 314, 1512-5.
17. Guidelines Subcommittee. 1999 World Health Organisation - International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens, 1999, 17, 151-83.
18. Held C, Hjemdahl P, Eriksson SV, Bjorkander I, Forslund L, Rehnqvist N. Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. Eur Heart J, 2001, 22, 62-72.
19. Katakami N, Yamasaki Y, Gorogawa S, et al. Additive metformin attenuates progression of intima-media thickness in subjects with type 2 diabetes treated with sulphonylureas [Abstract]. Diabetologia, 2002, 45 (suppl. 2), A274.
20. Sirtori CR, Franceschini G, Gianfranceschi G, et al. Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 1984, 6, 914-23.
21. Massad L, Plotkine M, Allix M, Boulu RG. Antithrombotic drugs in a carotid occlusion model: beneficial effect of the antidiabetic agent, metformin. Diabete Metab, 1988, 14, 544-8.
22. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol, 2001, 24, 151-8.
23. Spijkerman AM, Dekker JM, Nijpels G, et al. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Eur J Clin Invest, 2002, 32, 924-30.
24. Janeczko D, Kopczynski J, Janeczko-Sosnowska E, Tuszynska A, Lewandowski Z. The combined metformin & sulfonylurea therapy does not increase the risk of death in type 2 diabetes mellitus [Abstract]. Diabetologia, 2001, 44 (suppl. 1), A234.
25. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care, 2002, 25, 2244-8.